Sandu Pharmaceuticals

Sandu Pharmaceuticals FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Sandu Pharmaceuticals (524703.BO) as of Oct 31, 2026 is 305.49 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 0.77 % — a change of 39,330.65% (higher).

FCF Conversion

305.49 %

YoY

39,330.65%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Sandu Pharmaceuticals is 2026 305.49 % . FCF Conversion Rate (FCF/EBITDA) of Sandu Pharmaceuticals was 2025 0.77 % . It decreases by 39,330.65% higher compared to the previous year.

The Sandu Pharmaceuticals FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
542.90 INR
Jan 1, 2020
845.42 INR
Jan 1, 2021
683.12 INR
Jan 1, 2022
6.78 INR
Jan 1, 2023
-55.75 INR
Jan 1, 2024
-45.51 INR
Jan 1, 2025
0.77 INR
Jan 1, 2026
305.49 INR
The Sandu Pharmaceuticals FCF Conversion history
YEARFCF ConversionYoY
305.49 %+39,330.65%
0.77 %-101.70%
-45.51 %-18.38%
-55.75 %-922.81%
6.78 %-99.01%
683.12 %-19.20%
845.42 %+55.72%
542.90 %+455.62%
97.71 %-90.35%
1,013.01 %-445.24%
-293.42 %-127.37%
1,071.89 %-356.56%
-417.79 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Sandu Pharmaceuticals Stock analysis

What does Sandu Pharmaceuticals do? Sandu Pharmaceuticals Ltd is a Mumbai-based company operating in the Consumer Staples sector, specifically within the consumer products industry. Listed on September 26, 1994, the firm manufactures and markets Ayurvedic medicines. Its product portfolio spans digestive health, immunity, muscle and bone health, respiratory health, and general wellness. Specific offerings address conditions such as constipation, hyperacidity, asthma, and colds, while also covering female, male, and mother-and-child wellness. The company utilizes in-house know-how from Sandu Brothers Private Limited for production and distributes its goods, including immunity kits and power herbs, through e-commerce marketplaces. Sandu Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sandu Pharmaceuticals stock

FCF Conversion Rate (FCF/EBITDA) of Sandu Pharmaceuticals is 305.49 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Sandu Pharmaceuticals changed from 0.77 % to 305.49 %, representing a 39,330.65% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Sandu Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Sandu Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Sandu Pharmaceuticals

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Sandu Pharmaceuticals